Want to see INAB full AI Analyst Report?
INAB Stock Chart & Stats
$1.20
$0.03(2.20%)
At close: 4:00 PM EDT
$1.20
$0.03(2.20%)
Day’s Range― - ―
52-Week Range$0.88 - $2.73
Previous CloseN/A
Volume7.02K
Average Volume (3M)43.54K
Market Cap
$12.62M
Enterprise Value$11.67
Total Cash (Recent Filing)$17.96M
Total Debt (Recent Filing)$2.18M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Nov 05, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding9,858,383
10 Day Avg. Volume51,779
30 Day Avg. Volume43,544
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside316.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow leverage limits interest and refinancing pressure while the company funds clinical development. This provides more financial flexibility than a heavily debt-funded biotech, although equity financing remains necessary.
Improving Loss And Cash-Burn TrendNarrowing losses and reduced cash burn indicate better spending discipline and could extend the time available to advance the pipeline. The improvement does not yet eliminate the need for external funding.
Focused Cancer Immunotherapy PipelineA focused gamma-delta T-cell platform targeting difficult cancers gives IN8bio multiple avenues for clinical value creation. Using both donor-derived and patient-derived approaches may broaden development options across cancer settings.
Bears Say
No Product RevenueWithout commercial revenue, IN8bio cannot internally fund operations or validate market demand through sales. Its financial outlook remains dependent on successful clinical development, regulatory progress, and eventual commercialization.
Persistent Negative Cash FlowContinued cash consumption requires recurring financing to sustain research and clinical programs. Even with improved burn, persistent negative free cash flow can constrain development choices and increase exposure to funding conditions.
Capital Erosion And Dilution RiskDeclining equity and assets reflect cumulative losses and reduce the financial cushion supporting clinical execution. The new at-the-market facility provides funding access but can increase dilution as shares are issued to finance operations.
IN8bio News
INAB FAQ
What was In8bio, Inc.’s price range in the past 12 months?
In8bio, Inc. lowest stock price was $0.88 and its highest was $2.73 in the past 12 months.
What is In8bio, Inc.’s market cap?
In8bio, Inc.’s market cap is $12.62M.
When is In8bio, Inc.’s upcoming earnings report date?
In8bio, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were In8bio, Inc.’s earnings last quarter?
In8bio, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.344 by $0.094.
Is In8bio, Inc. overvalued?
According to Wall Street analysts In8bio, Inc.’s price is currently Undervalued.
Does In8bio, Inc. pay dividends?
In8bio, Inc. does not currently pay dividends.
What is In8bio, Inc.’s EPS estimate?
In8bio, Inc.’s EPS estimate is -0.31.
How many shares outstanding does In8bio, Inc. have?
In8bio, Inc. has 9,858,383 shares outstanding.
What happened to In8bio, Inc.’s price movement after its last earnings report?
In8bio, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.344. Following the earnings report the stock price went up 0.929%.
Which hedge fund is a major shareholder of In8bio, Inc.?
Currently, no hedge funds are holding shares in INAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
In8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
INAB Stock 12 Month Forecast
Average Price Target
$5.00
▲(316.67% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
―
Aprea Therapeutics
―
Ownership Overview
5.03% Insiders
4.49% Mutual Funds
34.48% Other Institutional Investors
55.09% Public Companies and
Individual Investors